Last edition
Home › News › Regulation
Symbiotec Pharmalab Receives VAI Status from US FDA
Symbiotec Pharmalab has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its manufacturing facility in Pithampur, Madhya Pradesh (MP), with a Voluntary Action Indicated (VAI) classification.
The FDA inspection was conducted from August 10 to 14, 2026.
The regulatory update was disclosed by the company to the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on September 29, 2026.
Read more on:
FDA VAI classification India Pithampur pharmaceutical manufacturing facility Symbiotec Pharmalab US FDA inspection Symbiotec Pithampur facility Symbiotec US FDA inspection US FDA Establishment Inspection Report US FDA pharmaceutical facility inspection
FDA VAI classification India Pithampur pharmaceutical manufacturing facility Symbiotec Pharmalab US FDA inspection Symbiotec Pithampur facility Symbiotec US FDA inspection US FDA Establishment Inspection Report US FDA pharmaceutical facility inspection
More news about: regulation | Published by News Bureau | September - 29 - 2026
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members